1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2026

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2026

  • November 2017
  • 413 pages
  • ID: 3091032
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2026

Summary
Prostate cancer (PCa) is the second most common cancer in men worldwide, after skin cancer. It accounts for 12% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems.

While patients diagnosed with early-stage, localized PCa can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options. Since 2010, five new drugs have been approved for the treatment of CRPC: Dendreon’sProvenge (sipuleucel-T), Sanofi’s Jevtana (cabazitaxel), Johnson & Johnson’s (J&J’s) Zytiga (abiraterone acetate), Astellas/Pfizer’s Xtandi (enzalutamide), and Bayer’s Xofigo (radium 223 dichloride).

It is estimated that the value of the prostate cancer (PCa) market in 2016 was about $7.7B across the 7MM. This market is defined as sales of major branded drugs commonly prescribed for PCa patients across the 7MM, excluding bone therapies. Over half of these sales, or about $4.5B (59%), were generated in the US, with the 5EU representing the next largest region by sales, estimated to be at around $2.1B (over 27%). Japan contributed the smallest proportion of sales to the global PCa market, with 2016 sales of just over $1B (about 13.9%).

By 2026, itis projected that the PCa sales will rise to about $13.7B in the 7MM, at a Compound Annual Growth Rate (CAGR) of about 6%.

Major drivers of the growth of the PCa market over the forecast period include -
- A rapidly aging population, resulting in PCa incident case increases in the markets covered in this report. Overall, across the 7MM, the diagnosed incidence of PCa is expected to increase by an Annual Growth Rate (AGR) of 1.7% from 2016'2026.
- The anticipated label extensions of Johnson & Johnson (J&J)’s Zytiga and Astellas/Pfizer’s Xtandi into hormone-sensitivePCa (HSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). Xtandi has become an established presence in the PCa treatment algorithm, and its extended use in multiple PCa patient segments, and its continued patent protection, ensures that it will be the market-leading PCa drug by the end of the forecast period in 2026.
- The launch of nine new premium-priced therapies for the treatment of PCa by 2026. GlobalData expects the launch of eight pipeline agents for castration-resistant prostate cancer (CRPC), and one for the treatment of localized PCa. In addition, weexpects label extensions for all second-generation hormonal agents in the treatment of HSPC.

The report "PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2026", provides the key metrics for prostate cancer in the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) covered in this report during the forecast period from 2016 to 2026.

In particular, this report provides the following -
- Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized prostate cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the prostate cancer therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for prostate cancer. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global prostate cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: AB Science, AbbVie, Advantagene, Amgen, Aptevo Therapeutics, Asana BioSciences

Scope
- Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized prostate cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the prostate cancer therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for prostate cancer. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global prostate cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global prostate cancer market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off

($10995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Prostate Specific Antigen - Pipeline Review, H2 2019

Prostate Specific Antigen - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Prostate Specific Antigen - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Prostate Specific Antigen - Pipeline Review, H2 2019’; Prostate Specific Antigen (Gamma Seminoprotein ...

Rectal Cancer Global Clinical Trials Review, H2, 2019

Rectal Cancer Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Rectal Cancer Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Rectal Cancer Global Clinical Trials Review, H2, 2019" provides an overview of Rectal Cancer clinical trials scenario.This ...

Metastatic Hormone Refractory Prostate Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Metastatic Hormone Refractory Prostate Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

  • $ 2000
  • January 2020

"Metastatic Hormone Refractory Prostate Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020" report offers comprehensive insights on marketed and Phase III products for Metastatic ...


ref:plp2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on